» Articles » PMID: 36849458

Longitudinal Assessment of Creatine Kinase, Creatine/Creatinine, and Myostatin As Monitoring Biomarkers in Becker Muscular Dystrophy

Abstract

Background And Objectives: The slow and variable disease progression of Becker muscular dystrophy (BMD) urges the development of biomarkers to facilitate clinical trials. We explored changes in 3 muscle-enriched biomarkers in serum of patients with BMD over 4-year time and studied associations with disease severity, disease progression, and dystrophin levels in BMD.

Methods: We quantitatively measured creatine kinase (CK) using the International Federation of Clinical Chemistry reference method, creatine/creatinine (Cr/Crn) using liquid chromatography-tandem mass spectrometry, and myostatin with ELISA in serum and assessed functional performance using the North Star Ambulatory Assessment (NSAA), 10-meter run velocity (TMRv), 6-Minute Walking Test (6MWT), and forced vital capacity in a 4-year prospective natural history study. Dystrophin levels were quantified in the tibialis anterior muscle using capillary Western immunoassay. The correlation between biomarkers, age, functional performance, mean annual change, and prediction of concurrent functional performance was analyzed using linear mixed models.

Results: Thirty-four patients with 106 visits were included. Eight patients were nonambulant at baseline. Cr/Crn and myostatin were highly patient specific (intraclass correlation coefficient for both = 0.960). Cr/Crn was strongly negatively correlated, whereas myostatin was strongly positively correlated with the NSAA, TMRv, and 6MWT (Cr/Crn rho = -0.869 to -0.801 and myostatin rho = 0.792 to 0.842, all < 0.001). CK showed a negative association with age ( = 0.0002) but was not associated with patients' performance. Cr/Crn and myostatin correlated moderately with the average annual change of the 6MWT (rho = -0.532 and 0.555, = 0.02). Dystrophin levels did not correlate with the selected biomarkers nor with performance. Cr/Crn, myostatin, and age could explain up to 75% of the variance of concurrent functional performance of the NSAA, TMRv, and 6MWT.

Discussion: Both Cr/Crn and myostatin could potentially serve as monitoring biomarkers in BMD, as higher Cr/Crn and lower myostatin were associated with lower motor performance and predictive of concurrent functional performance when combined with age. Future studies are needed to more precisely determine the context of use of these biomarkers.

Citing Articles

Serum Creatine Levels as a Predictive Factor for Postoperative Cerebrovascular Events in Patients With Moyamoya Disease.

Mou S, Zhao Z, Liu C, Li J, He Q, Liu W Brain Behav. 2025; 15(2):e70331.

PMID: 39935209 PMC: 11814481. DOI: 10.1002/brb3.70331.


A cross-sectional and longitudinal evaluation of serum creatinine as a biomarker in spinal muscular atrophy.

Zhao X, Gong Z, Luo H, Li Z, Gao R, Yang K Orphanet J Rare Dis. 2024; 19(1):489.

PMID: 39722044 PMC: 11670464. DOI: 10.1186/s13023-024-03515-0.


The Relevance of Spinal Muscular Atrophy Biomarkers in the Treatment Era.

Maretina M, Koroleva V, Shchugareva L, Glotov A, Kiselev A Biomedicines. 2024; 12(11).

PMID: 39595052 PMC: 11591959. DOI: 10.3390/biomedicines12112486.


Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.

Mackels L, Mariot V, Buscemi L, Servais L, Dumonceaux J Int J Mol Sci. 2024; 25(16).

PMID: 39201450 PMC: 11354404. DOI: 10.3390/ijms25168763.


Age-Related Blood Levels of Creatine Kinase-MM in Newborns and Patients with Duchenne Muscular Dystrophy: Considerations for the Development of Newborn Screening Algorithms.

Potter S, Migliore B, Carter J, Copeland V, Smith E, Peay H Int J Neonatal Screen. 2024; 10(2).

PMID: 38920848 PMC: 11203585. DOI: 10.3390/ijns10020041.


References
1.
Kerr K, Roth J, Zhu K, Thiessen-Philbrook H, Meisner A, Wilson F . Evaluating biomarkers for prognostic enrichment of clinical trials. Clin Trials. 2017; 14(6):629-638. PMC: 5714681. DOI: 10.1177/1740774517723588. View

2.
McPherron A, Lawler A, Lee S . Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 1997; 387(6628):83-90. DOI: 10.1038/387083a0. View

3.
Ferlini A, Flanigan K, Lochmuller H, Muntoni F, t Hoen P, McNally E . 204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24-26 January 2014, Naarden, The Netherlands. Neuromuscul Disord. 2014; 25(2):184-98. PMC: 4534085. DOI: 10.1016/j.nmd.2014.09.004. View

4.
Bello L, Campadello P, Barp A, Fanin M, Semplicini C, Soraru G . Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathies. Sci Rep. 2016; 6:32439. PMC: 5007528. DOI: 10.1038/srep32439. View

5.
. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View